Holen Sie sich die Stockscreener-App
0.1988
23.33%
-0.0605
Handel nachbörslich:
.21
0.0112
+5.63%
Schlusskurs vom Vortag:
$0.2593
Offen:
$0.2593
24-Stunden-Volumen:
13.60M
Relative Volume:
9.26
Marktkapitalisierung:
$5.37M
Einnahmen:
$9.94M
Nettoeinkommen (Verlust:
$-144.49M
KGV:
-0.0355
EPS:
-5.5956
Netto-Cashflow:
$-103.90M
1W Leistung:
-93.85%
1M Leistung:
-89.86%
6M Leistung:
-96.35%
1J Leistung:
-93.33%
1-Tages-Spanne:
$0.183
$0.2598
1-Wochen-Bereich:
$0.183
$3.38
52-Wochen-Spanne:
$0.183
$8.17
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Firmenname
Syros Pharmaceuticals Inc
Sektor
Branche
Telefon
617-744-1340
Adresse
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Vergleichen Sie SYRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SYRS | 0.1988 | 5.37M | 9.94M | -144.49M | -103.90M | -5.5956 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-08 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2019-02-14 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-11-05 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-03-13 | Bestätigt | Wedbush | Outperform |
| 2017-10-31 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-23 | Eingeleitet | ROTH Capital | Neutral |
| 2017-08-10 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
Alle ansehen
Syros Pharmaceuticals Inc Aktie (SYRS) Neueste Nachrichten
What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com
Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online
Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline
Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks
Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat
JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace
TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com
Syros downgraded to Market Perform from Outperform at JMP Securities - TipRanks
Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Syros Pharmaceuticals trial fails to meet primary goal - Investing.com
Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress By Investing.com - Investing.com South Africa
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com India
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlight - GuruFocus.com
Syros Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update - BioSpace
Syros Pharmaceuticals Q3 2024 Earnings Preview - MSN
Q3 2024 Syros Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday - MarketBeat
Finanzdaten der Syros Pharmaceuticals Inc-Aktie (SYRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):